Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03864328




Registration number
NCT03864328
Ethics application status
Date submitted
2/03/2019
Date registered
6/03/2019

Titles & IDs
Public title
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
Scientific title
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial
Secondary ID [1] 0 0
RVT1601-CC-04
Universal Trial Number (UTN)
Trial acronym
SCENIC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Persistent Cough in IPF 0 0
Chronic Cough 0 0
IPF 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - RVT-1601
Treatment: Drugs - Placebo

Experimental: RVT-1601 Low Dose -

Experimental: RVT-1601 Mid Dose -

Experimental: RVT-1601 High Dose -

Placebo comparator: Placebo -


Treatment: Drugs: RVT-1601
Inhaled RVT-1601 administered TID via eFlow nebulizer

Treatment: Drugs: Placebo
Inhaled Placebo administered TID via eFlow nebulizer
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in 24-hour average cough count
Timepoint [1] 0 0
12 weeks
Secondary outcome [1] 0 0
Change in cough severity
Timepoint [1] 0 0
12 weeks
Secondary outcome [2] 0 0
Change in cough-specific QoL
Timepoint [2] 0 0
12 weeks

Eligibility
Key inclusion criteria
* Male or female subjects age 40 through 89 years
* Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines
* Persistent cough for at least 8 weeks that is primarily due to IPF and not responsive to anti-tussive therapy
* Daytime cough severity score of = 40 mm on a 100-mm VAS
* 24-hour average cough count of at least 10 coughs per hour
* Forced Vital Capacity (FVC) > 45% predicted value within 4 weeks
* Diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) > 30% predicted value within 4 weeks
* Life expectancy of at least 12 months
Minimum age
40 Years
Maximum age
89 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could place the subject at risk or compromise the quality of the study data
* Significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month)
* Upper or lower respiratory tract infection within 4 weeks
* Acute exacerbation of IPF within 6 months
* Lung transplantation expected within 12 months
* Requiring supplemental O2 > 4 litres/min to maintain peripheral arterial O2 saturation (SpO2) > 88% at rest
* History of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 2 years
* Current smoker (i.e., use of tobacco products within the last 3 months)
* Current or recent history of drug or alcohol abuse within 12 months
* Participation in any other investigational drug study within 4 weeks
* Use of certain drugs for cough management within 4 weeks: prednisone, opiates, baclofen, gabapentin, pregabalin, thalidomide, amitriptyline, inhaled corticosteroids, or inhaled bronchodilators
* Use of ACE inhibitors or cromolyn sodium within 4 weeks
* Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control during the study
* History of hypersensitivity or intolerance to cromolyn sodium

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/06/2020
Sample size
Target
Accrual to date
Final
108
Recruitment in Australia
Recruitment state(s)
NSW,QuenslandSA,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Lung Research Quensland - Chermside
Recruitment hospital [4] 0 0
Mater Research - South Brisbane
Recruitment hospital [5] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [6] 0 0
Frankston Hospital-Peninsula Health - Frankston
Recruitment hospital [7] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [8] 0 0
Alfred Health - Westmead
Recruitment hospital [9] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [10] 0 0
Trialswest - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
3199 - Frankston
Recruitment postcode(s) [7] 0 0
3084 - Heidelberg
Recruitment postcode(s) [8] 0 0
3004 - Westmead
Recruitment postcode(s) [9] 0 0
6150 - Murdoch
Recruitment postcode(s) [10] 0 0
6150 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Belgium
State/province [22] 0 0
Brussel
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Canada
State/province [24] 0 0
Halifax
Country [25] 0 0
Canada
State/province [25] 0 0
Hamilton
Country [26] 0 0
Canada
State/province [26] 0 0
Montréal
Country [27] 0 0
Canada
State/province [27] 0 0
Toronto
Country [28] 0 0
Canada
State/province [28] 0 0
Vancouver
Country [29] 0 0
Czechia
State/province [29] 0 0
Prague
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Germany
State/province [31] 0 0
Bonn
Country [32] 0 0
Germany
State/province [32] 0 0
Essen
Country [33] 0 0
Germany
State/province [33] 0 0
Greifenstein
Country [34] 0 0
Germany
State/province [34] 0 0
Hannover
Country [35] 0 0
Germany
State/province [35] 0 0
Heidelberg
Country [36] 0 0
Germany
State/province [36] 0 0
Immenhausen
Country [37] 0 0
Germany
State/province [37] 0 0
Solingen
Country [38] 0 0
Italy
State/province [38] 0 0
Bologna
Country [39] 0 0
Italy
State/province [39] 0 0
Catania
Country [40] 0 0
Italy
State/province [40] 0 0
Modena
Country [41] 0 0
Italy
State/province [41] 0 0
Padova
Country [42] 0 0
Italy
State/province [42] 0 0
Roma
Country [43] 0 0
Italy
State/province [43] 0 0
Siena
Country [44] 0 0
Italy
State/province [44] 0 0
Torino
Country [45] 0 0
Netherlands
State/province [45] 0 0
Amsterdam
Country [46] 0 0
Netherlands
State/province [46] 0 0
Den Haag
Country [47] 0 0
Netherlands
State/province [47] 0 0
Heerlen
Country [48] 0 0
Netherlands
State/province [48] 0 0
Nieuwegein
Country [49] 0 0
Netherlands
State/province [49] 0 0
Rotterdam
Country [50] 0 0
New Zealand
State/province [50] 0 0
Auckland
Country [51] 0 0
New Zealand
State/province [51] 0 0
Christchurch
Country [52] 0 0
New Zealand
State/province [52] 0 0
Hamilton
Country [53] 0 0
Turkey
State/province [53] 0 0
Adana
Country [54] 0 0
Turkey
State/province [54] 0 0
Istanbul
Country [55] 0 0
Turkey
State/province [55] 0 0
Izmir
Country [56] 0 0
United Kingdom
State/province [56] 0 0
East Yorkshire
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Cambridge
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Edinburgh
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Leicester
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Liverpool
Country [61] 0 0
United Kingdom
State/province [61] 0 0
London
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Manchester
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Nottingham
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Respivant Sciences GmbH
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Respivant Sciences Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ahmet Tutuncu, MD, PhD
Address 0 0
Respivant Sciences Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03864328